Vireo GrowthFRA:K95 -5.39%44 Operating Margin % is 16.67% as of Mar. 2026. GuruFocus rates FRA:K95 with a GF Score™ of 44/100 and a GF Value™ of €7.54 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 955 Drug Manufacturers companies, Vireo Growth ranks worse than 51.2% on this metric.
Operating Margin % is calculated as Operating Income divided by its Revenue. Vireo Growth's Operating Income for the
three
months ended in Mar. 2026 was €15.3 Mil. Vireo Growth's Revenue for the
three
months ended in Mar. 2026 was €91.9 Mil. Therefore, Vireo Growth's Operating Margin % for the quarter that ended in Mar. 2026 was 16.67%.
The historical rank and industry rank for Vireo Growth's Operating Margin % or its related term are showing as below:
FRA:K95'
s Operating Margin % Range Over the Past 10 Years
Min: -74.67 Med: -9.3 Max: 18.18
Current: 7.01
FRA:K95's Operating Margin % is ranked worse than 51.2% of 955
companies
in the Drug Manufacturers industry
Industry Median: 7.45
vs FRA:K95: 7.01
Vireo Growth's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.
Vireo Growth's Operating Income for the
three
months ended in Mar. 2026 was €15.3 Mil.
Its Operating Income for the trailing twelve months (TTM) ended in Mar. 2026 was €21.3 Mil.
Warning Sign:
Vireo Growth Inc has recorded a loss in operating income at least once over the past 3 years.
Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.
Be Aware
Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).
If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.
For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokias Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).
Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.
Vireo Growth Operating Margin % Related Terms
Vireo Growth Operating Margin % Historical Data
* Premium members only.
The historical data trend for Vireo Growth's Operating Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Vireo Growth's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vireo Growth Operating Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vireo Growth's Operating Margin % distribution charts can be found below:
* The bar in red indicates where Vireo Growth's Operating Margin % falls into.
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
Vireo Growth's Operating Margin % for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vireo Growth (FRA:K95) has a Operating Margin % of 16.67% as of Mar. 2026. Operating margin is the ratio of total operating income to net sales. View historical data on Vireo Growth and its competitors. According to the industry distribution chart, Vireo Growth ranks #489 out of 955 companies in the Drug Manufacturers industry, placing it in the top 51.2%.
Is Vireo Growth's Operating Margin % too high?
Vireo Growth's current Operating Margin % is 16.67%. The Drug Manufacturers industry median Operating Margin % is 7.45. Vireo Growth's value of 16.67% is 123.8% above this industry median. Based on the distribution chart, Vireo Growth ranks #489 out of 955 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Vireo Growth has a GF Score™ of 44/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Vireo Growth's Operating Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Vireo Growth ranks #489 out of 955 companies for Operating Margin %. This places Vireo Growth in the lower half of its industry. The industry median Operating Margin % is 7.45. Vireo Growth's value of 16.67% is 123.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Drug Manufacturers company?
The median Operating Margin % among Drug Manufacturers companies is 7.45, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a Operating Margin % significantly above this median, while those in the bottom quartile fall well below. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vireo Growth's current Operating Margin % of 16.67% is 123.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on Vireo Growth and its competitors. For the Drug Manufacturers industry, the median Operating Margin % is 7.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vireo Growth's current Operating Margin % is 16.67%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vireo Growth stock overvalued right now?
Based on GuruFocus' analysis, Vireo Growth (FRA:K95) is currently considered Modestly Overvalued. The stock's GF Value™ is €7.54, compared to a current price of €8.42 — trading 11.7% above its estimated fair value. The current Operating Margin % is 16.67% and 123.8% above the Drug Manufacturers industry median of 7.45. Vireo Growth's overall GF Score™ is 44/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For Vireo Growth (FRA:K95), the current Operating Margin % is 16.67% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vireo Growth (FRA:K95) Overvalued in 2026?
Based on GuruFocus' analysis, Vireo Growth stock appears to be overvalued.
The current stock price of €8.42 is trading 11.7% above its estimated GF Value™ of €7.54.
GuruFocus considers Vireo Growth to be Modestly Overvalued.
Key valuation signals for FRA:K95:
Operating Margin %: 16.67%
GF Value™: €7.54 vs. price of €8.42 (11.7% above fair value)
Industry Position: 123.8% above the Drug Manufacturers median (#489 of 955)
No single metric tells the full story. See the FRA:K95 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vireo Growth Incis a cannabis company whose mission is to provide safe access, quality products and value to its customers while supporting its local communities through active participation and restorative justice programs. The Company is evolving with the industry and is in the midst of a transformation to being significantly more customer-centric across its operations, which include cultivation, manufacturing, wholesale and retail business lines. The company operates in one single segment.
44GF Score
Get the complete analysis for FRA:K95
Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:K95 has been successfully added to your 
